Skip to main content

Table 2 Clinical characteristics (A) and outcomes (B) in the cohort of breast cancer patients (N = 457) and their correlation with BRCA mutation and non-BRCA mutation carrying status

From: Germline breast cancer susceptibility gene mutations and breast cancer outcomes

  No mutation BRCA mutation Non-BRCA mutation
N = 397 N = 36 P-value* N = 24 P-value*
A. Clinical characteristics
Age of onset, mean (SD)   41.7 (9.9) 42.1 (10.1) 0.846 42.3 (11.4) 0.771
   no. (%) no. (%)   no. (%)  
Lymph node positive 160 (42.6) 20 (66.7) 0.011 8 (36.4) 0.568
negative 216 (57.5) 10 (33.3)   14 (63.6)  
Tumor size ≤ 2 cm 194 (52.3) 16(55.2) 0.765 13 (59.1) 0.535
>  2 cm 177 (47.7) 13 (44.8)   9 (40.9)  
Surgery type MRM 246 (62.1) 29 (80.6) 0.028 14 (58.3) 0.711
BCT 150 (37.9) 7 (19.4)   10 (41.7)  
Chemotherapy yes 323 (82.0) 36 (100) 0.005 17 (70.8) 0.174
no 71 (18.0) 0 (0)   7 (29.2)  
Radiotherapy yes 275 (69.8) 29 (82.9) 0.103 16 (66.7) 0.746
no 119 (30.2) 6 (17.1)   8 (33.3)  
Hormonal therapy yes 217 (57.7) 21 (70) 0.189 12 (54.5) 0.770
no 159 (42.3) 9 (30)   10 (45.5)  
Stage 0 (DCIS) 11 (2.8) 0 (0) 0.307 1 (4.2) 0.704
1 138 (35.0) 8 (23.5)   11 (45.8)  
2 159 (40.4) 15 (44.1)   10 (41.7)  
3 48 (12.2) 8 (23.5)   1 (4.2)  
4 7 (1.8) 0 (0)   0 (0)  
LABC 31 (7.9) 3 (8.8)   1 (4.2)  
Triple negative yes 108 (27.2) 9 (25.0) 0.776 9 (37.5) 0.274
no 289 (72.8) 27 (75.0)   15 (62.5)  
ER positive 234 (59.5) 24 (66.7) 0.403 12 (52.2) 0.485
negative 159 (40.5) 12 (33.3)   11 (47.8)  
HER2 overexpression yes 72 (19.8) 3 (8.8) 0.118 3 (14.3) 0.537
no 292 (80.2) 31 (91.2)   18 (85.7)  
Nuclear grade 1 51 (13.9) 1 (3.5) 0.276 3 (14.3) 0.896
2 123 (33.5) 11 (37.9)   8 (38.1)  
3 193 (52.6) 17 (58.6)   10 (47.6)  
Lymphovascular invasion prominent 82 (22.1) 11 (37.9) 0.122 2 (9.5) 0.259
focal 104 (28.0) 8 (27.6)   5 (23.8)  
absent 185 (49.9) 10 (34.5)   14 (66.7)  
B. Outcomes
Recurrence† 53 (13.4) 11 (30.6) 0.005 1 (4.2) 0.191
 Distant metastasis 38 (9.6) 9 (25.0) 0.004 0 (0) 0.112
 Locoregional recurrence only 15 (3.8) 2 (5.6) 0.599 1 (4.2) 0.923
Death 12 (3.0) 3 (8.3) 0.095 0 (0) 0.388
  1. SD: standard deviation; MRM: modified radical mastectomy; BCT: breast conserving therapy; DCIS: ductal carcinoma in situ; LABC: locally advanced breast cancer; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2. * P-values were calculated using Chi-square test for categorical variables and t-test for continuous variables (age). The statistically significant values (< 0.05) are shown in bold. † Recurrence includes distant metastasis, local/ipsilateral breast and regional recurrence, and does not include contralateral breast cancer or second primary cancer